SJ-3149, a selective CK1α degrader with activity across a range of hematologic and solid tumors
Jan. 22, 2024
Researchers from St. Jude Children’s Research Hospital have reported the discovery of SJ-3149, a novel selective CK1α degrader being developed for the treatment of cancer.
